JPMorgan Chase & Co. Has $4.46 Million Stock Holdings in 4D Molecular Therapeutics, Inc. $FDMT
JPMorgan Chase & Co. reduced its stake in 4D Molecular Therapeutics (NASDAQ:FDMT) by 42.2% in the third quarter, now holding 513,515 shares valued at $4.46 million. Despite this reduction, institutional investors collectively own 99.27% of the stock. Analyst sentiment remains largely positive with a "Moderate Buy" consensus and an average price target of $31.25, following a strong earnings beat where the company reported $0.43 EPS against a -$0.53 consensus and $85.09M revenue versus $30.86M expected.
FDMT SEC Filings - 4D Molecular Therapeutics Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for 4D Molecular Therapeutics (FDMT) SEC filings, including annual reports, quarterly earnings, material events, and insider trading forms. It highlights recent Form 8-K filings detailing clinical trial data, collaborations, and executive appointments. The platform also offers AI-powered summaries and sentiment analysis for these regulatory documents.
4D Molecular Therapeutics, Inc. $FDMT Shares Sold by Assenagon Asset Management S.A.
Assenagon Asset Management S.A. significantly reduced its stake in 4D Molecular Therapeutics (NASDAQ:FDMT) by 55.4% in the fourth quarter, selling 367,458 shares and retaining 296,199 shares valued at $2.22 million. Despite this, other institutional investors have recently increased their holdings, and the company reported strong Q4 earnings, beating analyst estimates with $0.43 EPS and $85.09 million in revenue. Analysts have a "Moderate Buy" consensus rating for FDMT with a $31.25 price target.
4D Molecular Therapeutics Inc (FDMT) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for 4D Molecular Therapeutics Inc (FDMT). It also mentions that Capital.com is an online trading platform.
4D Molecular Therapeutics (NASDAQ: FDMT) elevates CFO Kristian Humer to Principal Accounting Officer
4D Molecular Therapeutics (NASDAQ: FDMT) has announced the appointment of Kristian Humer, their current Chief Financial Officer and Principal Financial Officer, to the additional role of Principal Accounting Officer. This change, effective March 25, 2026, consolidates key finance and accounting responsibilities under Mr. Humer, who succeeds Ashoo Gupta. Ms. Gupta will continue with the company as Vice President, Finance and Controller.
4D Molecular Therapeutics appoints Kristian Humer as Principal Accounting Officer
4D Molecular Therapeutics has appointed Kristian Humer as its new Principal Accounting Officer, effective March 25, 2026. He succeeds Ashoo Gupta, who will continue in his role as Vice President, Finance and Controller. Humer brings extensive experience, having previously served as CFO at other biotechnology companies.
Jefferies Initiates 4D Molecular Therapeutics(FDMT.US) With Buy Rating, Announces Target Price $21
Jefferies has initiated coverage on 4D Molecular Therapeutics (FDMT.US) with a 'Buy' rating. Analyst Faisal Khurshid set a target price of $21 for the stock. Khurshid boasts a 62.9% success rate and an average return of 65.0% over the past year, according to TipRanks data.
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at Jefferies Financial Group
Jefferies Financial Group has reaffirmed its "Buy" rating for 4D Molecular Therapeutics (NASDAQ:FDMT) but lowered its price target from $40 to $21, still implying a 127% upside. Despite beating Q4 earnings and revenue expectations, the company remains unprofitable. The consensus among analysts is a "Moderate Buy" with an average price target of $31.25.
Jefferies cuts 4D Molecular Therapeutics stock price target on valuation By Investing.com
Jefferies has lowered its price target for 4D Molecular Therapeutics (NASDAQ:FDMT) to $21.00 from $40.00, while maintaining a Buy rating. The firm highlights the company's gene therapy approach for wet AMD with pivotal trials ongoing, and notes the stock is trading near cash levels, appearing undervalued according to InvestingPro analysis. RBC Capital also recently raised its price target for FDMT to $35 from $32.
4D Molecular (NASDAQ: FDMT) awards 217,000 stock options to CLO
4D Molecular Therapeutics (NASDAQ: FDMT) has granted its Chief Legal Officer, Scott Bizily, 217,000 stock options. These options have an exercise price of $9.88 per share and vest in equal monthly installments over four years, contingent on continuous service. This award is part of compensation, not an open-market transaction, and expires on March 24, 2036.
CEO at 4D Molecular (NASDAQ: FDMT) awarded 750K stock options
David Kirn, CEO of 4D Molecular Therapeutics (NASDAQ: FDMT), has been granted a stock option for 750,000 shares of common stock. The options have an exercise price of $9.88 per share and will vest monthly over four years, contingent on his continued employment. This grant, expiring on March 24, 2036, is a form of compensation aimed at aligning incentives and retaining the CEO, rather than a market purchase.
4D Molecular (NASDAQ: FDMT) awards 219,000 stock options to company officer
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) has awarded 219,000 stock options to Christopher Paul Simms, an officer of the company, as reported in a recent SEC Form 4 filing. The options have an exercise price of $9.88 per share and will vest monthly over four years, provided Simms remains a service provider. These options are set to expire on March 24, 2036.
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Given Consensus Recommendation of "Moderate Buy" by Brokerages
4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has received a consensus "Moderate Buy" rating from brokerages, with an average one-year price target of $32.71. The company recently exceeded quarterly earnings and revenue expectations, reporting $0.43 EPS against a -$0.53 consensus and $85.09M in revenue against $30.86M. Approximately 99.27% of the stock is held by institutional investors and hedge funds.
4D Molecular Therapeutics (NASDAQ:FDMT) Sees Unusually-High Trading Volume - Here's Why
4D Molecular Therapeutics (NASDAQ:FDMT) experienced an 86% surge in trading volume on Thursday, with its stock trading around $10.36. The company recently reported unexpected quarterly EPS of $0.43 and revenue of $85.09M, significantly beating estimates, but remains unprofitable. Analysts maintain an average "Moderate Buy" rating with an average price target of $32.71, and several institutional investors have increased their stakes in the company.
Vanguard amendment shows 0 shares of 4D Molecular (NASDAQ: FDMT)
The Vanguard Group filed an amended Schedule 13G/A for 4D Molecular Therapeutics Inc. (NASDAQ: FDMT), reporting 0 shares beneficially owned and 0% of the class. This change is due to an internal realignment effective January 12, 2026, where certain Vanguard subsidiaries will now report beneficial ownership separately, as per SEC Release No. 34-39538. This filing indicates that The Vanguard Group itself no longer claims beneficial ownership over FDMT shares.
4D Molecular Therapeutics (NASDAQ:FDMT) Trading 8.7% Higher - Here's Why
4D Molecular Therapeutics (NASDAQ:FDMT) saw its stock trade up 8.7% after reporting a surprise Q4 earnings beat, with EPS of $0.43 against an expected -$0.53 and revenue of $85.09M exceeding $30.86M consensus. Despite remaining unprofitable, the clinical-stage gene therapy company holds a "Moderate Buy" consensus rating from analysts, with institutional ownership at 99.27%. Several brokerage firms have recently reiterated "buy" or "outperform" ratings and raised price targets for FDMT.
VP Gupta of 4d molecular sold $3357 in FDMT stock
Ashoo Gupta, VP at 4D Molecular Therapeutics, sold 390 shares of FDMT stock for $3357, while also acquiring shares through Restricted Stock Unit conversions on March 20, 2026. This transaction occurred as FDMT shares have seen a significant 134% surge over the last year. The company is also making strides in clinical trials, with RBC Capital reiterating an Outperform rating and raising its price target due to progress in its wet age-related macular degeneration study and plans for a diabetic macular edema trial.
VP Gupta of 4d molecular sold $3357 in FDMT stock
Ashoo Gupta, VP, Finance and Controller at 4D Molecular Therapeutics (NASDAQ:FDMT), sold 390 shares of common stock for $3,357. The transaction occurred after FDMT shares surged 134% over the past year, and coincided with Gupta also acquiring 1,086 shares through Restricted Stock Unit conversions. Despite the sale, InvestingPro analysis suggests the stock is undervalued, and RBC Capital has raised its price target for 4D Molecular due to positive clinical trial progress.
VP Gupta of 4d molecular sold $3357 in FDMT stock By Investing.com
Ashoo Gupta, VP, Finance and Controller at 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), sold 390 shares of common stock worth $3357, while also acquiring 1086 shares through RSU conversion. This transaction comes as the company's stock has surged 134% in the past year. RBC Capital recently raised its price target for 4D Molecular to $35, maintaining an Outperform rating, due to positive developments in its clinical trials, especially for wet age-related macular degeneration.
4D Molecular (NASDAQ: FDMT) VP uses share sale to cover taxes
Ashoo Gupta, VP of 4D Molecular Therapeutics (NASDAQ: FDMT), recently exercised restricted stock units (RSUs) converting into 1,086 shares. Concurrently, 390 common shares were sold at $8.61 each in an automatic "sell-to-cover" transaction to fulfill tax withholding obligations, rather than a discretionary sale. Following these transactions, Gupta directly holds 47,055 common shares, with additional RSU awards set to vest quarterly starting June 20, 2025.
4D Molecular Therapeutics, Inc. (FDMT) Q4 earnings and revenues beat estimates
4D Molecular Therapeutics, Inc. (FDMT) announced strong financial results for Q4, beating analyst estimates for both earnings and revenue. The company reported a loss per share of $0.84, which was better than the consensus estimate of a $0.93 loss and significantly improved from the prior year's $1.09 loss. Revenues reached $3.3 million, exceeding expectations of $2.25 million.
Analysts Offer Insights on Healthcare Companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK) and Acrivon Therapeutics, Inc. (ACRV)
Analysts have issued bullish sentiments on three healthcare companies: 4D Molecular Therapeutics (FDMT), Scholar Rock Holding (SRRK), and Acrivon Therapeutics, Inc. (ACRV). H.C. Wainwright reiterated a Buy rating on FDMT with a $36.00 price target, Cantor Fitzgerald maintained a Buy rating on SRRK, and H.C. Wainwright also maintained a Buy rating on ACRV with a $19.00 price target. The average price targets imply significant upside potential for all three stocks based on current analyst consensus.
4D Molecular Therapeutics (FDMT) Receives a Hold from Cantor Fitzgerald
Cantor Fitzgerald analyst Joshua Schimmer maintained a Hold rating on 4D Molecular Therapeutics (FDMT) with the company's shares closing at $8.56 yesterday. The analyst has a 16.2% average return and 50.63% success rate on recommended stocks. Despite this, the analyst consensus on FDMT is a Moderate Buy with a 265.07% upside, with TipRanks also reiterating a Hold rating with an $8.50 price target.
4D Molecular Therapeutics' (FDMT) "Buy" Rating Reaffirmed at HC Wainwright
HC Wainwright has reaffirmed its "Buy" rating for 4D Molecular Therapeutics (FDMT) with a price target of $36.00, suggesting a significant upside. The company recently reported an earnings beat with EPS of $0.43 and revenue of $85.09 million, though it remains unprofitable. Analyst consensus for FDMT is a "Moderate Buy" with an average price target of $32.71.
Reimbursement and Pricing Pressures Threaten Commercial Outlook for 4D Molecular Therapeutics’ Gene Therapies
4D Molecular Therapeutics, Inc. (FDMT) faces significant commercial risks for its gene therapy candidates due to potential reimbursement and pricing pressures. Government authorities and private payors could limit uptake through constrained coverage and restrictive pricing frameworks, negatively impacting the recovery of development costs. The challenges stem from global healthcare cost containment efforts, mandatory discounts, and the need to prove superior outcomes against cheaper standard-of-care therapies, which could hinder the company's revenue growth.
4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank Of Canada
Royal Bank of Canada has raised its price target for 4D Molecular Therapeutics (NASDAQ:FDMT) to $35.00, maintaining an "outperform" rating, which suggests a significant upside potential of around 295%. This adjustment follows the company's strong quarterly earnings report, which exceeded revenue and EPS estimates despite negative net margins. The stock shows a "Moderate Buy" consensus among analysts, with institutional investors holding a substantial portion of shares.
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative
4D Molecular Therapeutics (FDMT) reported a significant Q4 2025 profit with revenue of US$85.1 million and EPS of US$0.30, contrasting sharply with previous quarters' losses, though the company remains unprofitable on a trailing twelve-month basis with a US$140.1 million net loss. Analysts question the sustainability of these recent gains, as five-year trends show widening losses and projected annual earnings decline. Despite a lower P/S ratio compared to the industry, the market remains cautious due to the company's persistent unprofitability and expected negative earnings for the next three years.
4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative
4D Molecular Therapeutics (FDMT) reported a surprising Q4 2025 profit with revenue of US$85.1 million and basic EPS of US$0.30, contrasting sharply with previous quarters of losses. While this marks a significant shift from their long-standing loss narrative, the company still faces a trailing twelve-month net loss of US$140.1 million, and analysts project further annual earnings declines. Investors are now evaluating the sustainability of this recent profitability against the backdrop of historical losses and future growth forecasts.
4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up After Analyst Upgrade
4D Molecular Therapeutics (NASDAQ:FDMT) saw its shares gap up after Royal Bank of Canada raised its price target to $35 and maintained an "outperform" rating. This upgrade follows a significant quarterly earnings beat, with the company reporting $0.43 EPS against an estimated -$0.53 and revenue of $85.09 million versus $30.86 million expected. Analyst sentiment is generally positive, and institutional investors hold a substantial 99.27% of the company's shares.
FDMT: Chardan Capital Maintains Buy Rating with Price Target of $26.00 | FDMT Stock News
Chardan Capital has reiterated its Buy rating for 4D Molecular Therapeutics (FDMT), maintaining a price target of $26.00. This continued endorsement reflects the firm's confidence in the gene therapy company's future performance. Analysts' average target price for FDMT is $32.63, suggesting a substantial upside from its current trading price, while GuruFocus estimates the fair value (GF Value) at $67.52.
RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk
RBC Capital Markets has increased its price target for 4D Molecular Therapeutics (FDMT) to $35 from $32, while maintaining an "Outperform" rating with a "Speculative Risk" caveat. The announcement was made on March 19, 2026, by MT Newswires.
4D Molecular Therapeutics, Inc. (FDMT) Q4 Results Surpass Forecasts for Earnings and Revenue
4D Molecular Therapeutics, Inc. (FDMT) reported strong Q4 results, significantly exceeding analyst expectations with earnings of $0.43 per share against a predicted loss, and achieving $85.09 million in revenue. The company's stock has risen 14.8% year-to-date, outperforming the S&P 500. While future forecasts are mixed, FDMT currently holds a Zacks Rank #3 (Hold).
4D Molecular Therapeutics (NASDAQ: FDMT) posts 2025 results, inks Otsuka deal, extends cash runway
4D Molecular Therapeutics (FDMT) reported its full-year 2025 financial results, highlighting a strategic partnership with Otsuka Pharmaceutical Co., Ltd. and a strengthened financial position. The company secured an $85 million upfront payment from Otsuka and extended its cash runway into the second half of 2028, largely due to this deal and additional equity financings. FDMT also made significant progress in its late-stage gene therapy pipeline, including completing enrollment for the 4FRONT-1 Phase 3 wet AMD trial ahead of schedule and advancing its 4D-710 program for cystic fibrosis.
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (4DMT) reported its full year 2025 financial results, highlighting significant progress in its clinical trials, including the rapid enrollment of its 4D-150 4FRONT-1 wet AMD Phase 3 trial. The company also strengthened its financial position with a strategic partnership with Otsuka and a successful $118 million financing, extending its cash runway into the second half of 2028. Key upcoming milestones include data readouts for 4D-150 in wet AMD and DME, and further development of its 4D-710 program for cystic fibrosis lung disease.
4DMT Reports Full Year 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones
4D Molecular Therapeutics (4DMT) reported its full-year 2025 financial results, highlighting significant progress in its clinical trials, including the rapid enrollment of the 4D-150 wet AMD Phase 3 trial. The company also strengthened its financial position through a strategic partnership with Otsuka and additional financing, extending its cash runway into the second half of 2028. Key upcoming milestones include topline data readouts for various trials and the initiation of a 4D-150 DME global Phase 3 trial.
4DMT to Participate in Upcoming Investor Meetings
4D Molecular Therapeutics (4DMT), a late-stage biotechnology company, announced its management will participate in investor meetings and present at upcoming investor conferences in March. The company will attend the Leerink Partners Mountain Meeting and the RBC Capital Markets Global Ophthalmology Conference. 4DMT is focused on developing durable, disease-targeted therapeutics, including lead product candidates 4D-150 for blinding retinal vascular diseases and 4D-710 for cystic fibrosis.
Biotech 4D Molecular Therapeutics lines up March investor conference talks
4D Molecular Therapeutics (Nasdaq: FDMT) announced that its management will participate in investor meetings and present at two upcoming conferences in March 2026: the Leerink Partners Mountain Meeting and the RBC Capital Markets Global Ophthalmology Conference. The company will also make an archived webcast of its RBC presentation available on its investor relations website for up to one year. This announcement focuses solely on conference participation and does not include financial results or guidance.
4DMT to Participate in Upcoming Investor Meetings
4D Molecular Therapeutics (4DMT) announced that its management will present and participate in one-on-one meetings at upcoming investor conferences in March. These include the Leerink Partners Mountain Meeting from March 22-25, 2026, and the RBC Capital Markets Global Ophthalmology Conference on March 24, 2026. The company, a late-stage biotechnology firm, is focused on developing durable, disease-targeted therapeutics for conditions like wet age-related macular degeneration and cystic fibrosis.
4D Molecular Therapeutics Highlights 4D-150 Phase III Momentum, DME Plans, Cash Runway at Leerink Conference
4D Molecular Therapeutics provided updates at the Leerink Partners Global Healthcare Conference on their late-stage ophthalmology program, commercialization planning, and cystic fibrosis development efforts. The company highlighted rapid enrollment completion for their 4D-150 gene therapy in wet AMD, its potential in diabetic macular edema (DME), and detailed its financial runway into the second half of 2028. They also discussed commercial models, market strategies, and pipeline progress for an inhaled gene therapy for cystic fibrosis.
FDMT: 4D-150's rapid phase III progress and broad commercialization plans highlight strong market potential
4D Molecular Therapeutics' lead asset, 4D-150, has achieved rapid Phase III enrollment, indicating a strong market need and physician interest. The company plans extensive commercialization strategies across the U.S., EU, and Asia-Pacific, expecting broad label approval and significant pricing flexibility. This progress, along with a cash runway extending into 2028, highlights the strong market potential of FDMT's 4D-150.
FDMT: Rapid phase 3 progress and strong market interest position 4D-150 for global commercialization
4D Molecular Therapeutics (FDMT) is rapidly advancing its 4D-150 programs for wet AMD and DME through phase 3 trials, driven by high demand from physicians and patients. The company has developed commercialization strategies for the U.S., Europe, and Asia-Pacific markets and is well-funded until 2028. Additionally, FDMT is progressing a promising cystic fibrosis program.
Fabry Disease Market: Rapid Growth & Investment Outlook to 2034 – DelveInsight | Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, AVROBIO, 4D Molecular Therapeutics
The Fabry Disease market is projected for rapid growth with an estimated value of USD 1,700 million in 2024 and significant CAGR through 2034. This growth is driven by increasing disease prevalence and awareness, coupled with the anticipated introduction of several pipeline therapies, especially Sangamo Therapeutics' ST-920, which is pursuing accelerated approval. Key companies like Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, and AVROBIO are actively involved in developing new treatments and shaping the market landscape.
Retinitis Pigmentosa Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | SparingVision SAS, ProQR Therapeutics NV, Viridian Therapeutics Inc, 4D Molecular Therapeutics Inc
The Retinitis Pigmentosa (RP) market, valued at approximately USD 500 million in 2023, is projected for significant growth through 2034 due to increasing prevalence and awareness, along with the launch of multiple pipeline products. Key companies like Ocugen, Nanoscope Therapeutics, and ViGeneron are advancing gene therapies, with several clinical trials showing promising results for different stages and types of RP. The report highlights a robust pipeline of emerging drugs, key market drivers, and opportunities, especially in gene and cell therapies, to address the unmet medical needs in RP treatment across the US, EU5, and Japan.
FDMT Technical Analysis & Stock Price Forecast
This article provides a technical analysis and stock price forecast for 4D Molecular Therapeutics Inc (FDMT). As of March 3, 2026, the overall technical consensus for FDMT is Neutral, with an aggregate of 14 technical signals showing an equal number of buy and sell indicators. Key metrics like RSI, MACD, and various moving averages are analyzed, alongside support and resistance levels.
FDMT Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a detailed financial overview of 4D Molecular Therapeutics Inc. (FDMT), covering its income statement, balance sheet, and cash flow for both annual and quarterly periods. It highlights the company's weak profitability, significant revenue decline, but strong balance sheet attributed to low debt and high liquidity. The analysis also includes detailed financial health signals, key metrics, and comparative data for similar companies.
Where is 4D Molecular Therapeutics (FDMT) Headed According to the Street?
4D Molecular Therapeutics (FDMT) recently completed enrollment for its Phase 3 clinical trial of 4D-150 for wet AMD, a significant milestone for the company. Barclays initiated coverage with an "Overweight" rating and a $33 price target, citing a positive outlook for the biotech industry in 2026 due to potential M&A activity and strong fundamentals. The article also notes that FDMT is considered one of the top gene therapy stocks by hedge funds, although it suggests certain AI stocks might offer greater upside.
FDMT Technical Analysis & ETF Price Forecast
This article provides a technical analysis and price forecast for 4D Molecular Therapeutics Inc (FDMT). It includes various technical indicators such as Moving Averages, RSI, and MACD, along with support and resistance levels. The overall technical sentiment for FDMT is currently neutral, with several moving averages indicating a buy signal.
Chardan Capital maintains 4D Molecular Therapeutics (FDMT) buy recommendation
Chardan Capital has reiterated its "buy" recommendation for 4D Molecular Therapeutics (FDMT). This suggests a positive outlook from the firm regarding the company's stock performance and future prospects.
4D Molecular Therapeutics (NASDAQ:FDMT) Stock Price Up 6.2% - Time to Buy?
4D Molecular Therapeutics (NASDAQ:FDMT) saw its stock price increase by 6.2% to $9.58 on Monday with lighter trading volume. The company, a clinical-stage gene therapy developer, holds a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of $33.25, despite some recent downgrades. Institutional investors have significantly increased their holdings in FDMT, which now has a market capitalization of $553 million.
Key Catalysts on the Horizon for 4D Molecular Therapeutics
4D Molecular Therapeutics is preparing for significant corporate updates, including its quarterly financial results and crucial Phase 3 data for its wet age-related macular degeneration gene therapy. Investors are closely monitoring the company's financial runway and clinical trial progress, particularly the "4FRONT" study's topline data expected later this year, which is vital for its long-term valuation.
